BLUE - ブル―バ―ド・バイオ （bluebird bio Inc.） ブル―バ―ド・バイオBLUEのチャート
BLUEの企業情報
| symbol | BLUE |
|---|---|
| 会社名 | bluebird bio Inc （ブル―バ―ド・バイオ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ブルーバード(bluebird bio Inc.)は臨床開発段階にあるバイオテクノロジー企業であり、重症及び癌の遺伝子治療の開発に集中する。同社はレンチウイルスに基づく遺伝子治療と遺伝子編集機能を通じて、これらの分野におけるさまざまなアプリケーションを備えた統合製品プラットフォームを作成した。同社の複数の遺伝病に対する遺伝子臨床プログラムは輸血依存性β-サラセミアと重症鎌状赤血球病（SCD）を治療するLentiGlobin製品候補、脳性副腎白質ジストロフィー（CALD）を治療するLenti-D製品候補を含む。同社の腫瘍学におけるプログラムはキメラ抗原受容体（CAR） T細胞受容体（TCR）療法を含むT細胞ベースの免疫療法の開発に集中する。同社の腫瘍のリード製品候補bb2121は多発性骨髄腫の治療のためのCAR T細胞産物候補である。同社はパイプラインに応用する可能のメガTAL /ホーミングエンドヌクレアーゼ遺伝子編集技術を利用する発見研究プログラムがある。 ブル―バ―ド・バイオは、米国のバイオ医薬品企業。遺伝性疾患や難病向けに遺伝子治療製品の開発を手掛ける。主要製品候補はレンチDと呼ばれる副腎白質ジストロフィ―の治療薬と、サラセミアおよび鎌状赤血球病治療薬のレンチグロビンである。また、がん治療分野にて、がん細胞を破壊し患者自身のT細胞の遺伝子組換えなどの研究開発を手掛ける。 bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit. |
| 本社所在地 | 60 Binney Street Cambridge MA 02142 USA |
| 代表者氏名 | Daniel S. Lynch ダニエルS.リンチ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 339-499-9300 |
| 設立年月日 | 33695 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 479人 |
| url | www.bluebirdbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/blue |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -444.21700 |
| 終値（lastsale） | 133.44 |
| 時価総額（marketcap） | 7226832311.04 |
| 時価総額 | 時価総額（百万ドル） 7380.099 |
| 売上高 | 売上高（百万ドル） 35.68700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 6458.457 |
| 当期純利益 | 当期純利益（百万ドル） -351.15500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 bluebird bio Inc revenues increased 1% to $23.8M. Net loss increased 87% to $261.1M. Revenues reflect Collaboration revenue increase of 78% to $23M. Higher net loss reflects Change in fair value of contingent consi increase of 72% to $796K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.41 to -$5.22. |
BLUEのテクニカル分析
BLUEのニュース
bluebird bio Sells Second Priority Review Voucher for $95 Million 2023/01/06 12:30:00 Wallstreet:Online
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million. bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA) approvals of ZYNTEGLO (betibeglogene autotemcel) for the treatment of beta-thalassemia
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023/01/05 13:00:00 Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the
bluebird bio Inc.’s Stock Price Relatively Up Recently, But Trouble Is Still Brewing 2023/01/03 15:00:00 Stocks Register
bluebird bio Inc. (NASDAQ:BLUE) traded at $6.92 at close of the session on Friday, 12/30/22, made an upward move of 0.58% on its previous day’s price. Looking at the stock we see that its previous close was $6.88 and the beta (5Y monthly) reads 1.00 with the day’s price range being $6.67 – $6.93. In … bluebird bio Inc.’s Stock Price Relatively Up Recently, But Trouble Is Still Brewing Read More »
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer 2023/01/03 13:00:00 Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings mor
Bluebird bio completes sale of priority review voucher to argenx (NASDAQ:BLUE) 2022/12/30 10:48:11 Seeking Alpha
bluebird bio (BLUE) has closed the sale of a rare pediatric disease priority review voucher ((PRV)) to Dutch biotech argenx SE (ARGX) for $102M in cash. Read the full story here.
Roadblocks To A Successful stocks: bluebird bio, Inc. (NASDAQ:BLUE 22.05%), Virgin Galactic Holdings, Inc. (NYSE:SPCE -17.46%) 2022/08/07 23:40:43 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Roadblocks To A Successful stocks: bluebird bio, Inc. (NASDAQ:BLUE 22.05%), Virgin Galactic Holdings, Inc. (NYSE:SPCE -17.46%) appeared first on Stocks Equity .
BLUE stock gains as earnings update draws upgrade at Barclays (NASDAQ:BLUE) 2022/08/05 15:10:48 Seeking Alpha
The shares of bluebird bio rose in the morning hours Friday after Barclays upgraded the gene therapy developer to Equal Weight from Underweight following the company’s 2Q 2022…
Barclays Upgrades bluebird bio to Equalweight 2022/08/05 15:03:02 Investing.com
https://www.investing.com/news/pro/barclays-upgrades-bluebird-bio-to-equalweight-432SI-2865504
bluebird bio PT Lowered to $10 at RBC Capital 2022/08/05 07:45:05 Investing.com
https://www.investing.com/news/pro/bluebird-bio-pt-lowered-to-10-at-rbc-capital-432SI-2864569
bluebird bio GAAP EPS of -$1.36 misses by $0.07, revenue of $1.52M beats by $0.81M (NASDAQ:BLUE) 2022/08/04 21:23:16 Seeking Alpha
bluebird bio press release (NASDAQ:BLUE): Q2 GAAP EPS of -$1.36 misses by $0.07.Revenue of $1.52M (-79.7% Y/Y) beats by $0.81M.Shares -2% AH.
Bluebird bio falls after Cowen downgrades rating 2022/04/06 15:26:27 Seeking Alpha
Bluebird Bio <> slides after brokerage Cowen downgrades to Market Perform from Outperform following the company''s restructuring announcement. Cowen analyst Yaron Werber has…
Bluebird Bio Joins Layoff Band Wagon As Gene Therapy Biotech Cuts Staff To Reduce Costs 2022/04/05 14:11:11 Benzinga
Bluebird Bio Inc (NASDAQ: BLUE ) is laying off about 30% of its workforce before the FDA decides the fate of two of its gene therapies. The gene therapy-focused company is showing the exit to nearly one-third of its staff to extend its cash runway into the first half of 2023 and save $160 million over the next two years. Bluebird plans to … Full story available on Benzinga.com
Bluebird bio to lay off nearly one-third of its employees as part of restructuring 2022/04/05 12:59:45 MarketWatch
Shares of Bluebird bio Inc. undefined fell 0.6% in premarket trading Tuesday, after the gene therapies company announced a restructuring save it $160 million…
Bluebird bio to cut 30% of workforce amid plans to target $160M cost savings (NASDAQ:BLUE) 2022/04/05 11:29:29 Seeking Alpha
Bluebird bio (BLUE) announced plans to reduce its staff by nearly 30% on Tuesday as the troubled gene therapy biotech targets up to $160 million in cost savings over the next two years in…
Bluebird bio to slash 30% of workforce as part of restructuring 2022/04/05 11:08:14 Financial Post
Gene therapy developer bluebird bio Inc on Tuesday said it would reduce its workforce by roughly 30%, or about 155 employees, as it seeks to save $160 million in costs over the next two years. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D’Silva)